This website uses cookies to store information on your computer. Some of these cookies are used for visitor analysis, others are essential to making our site function properly and improve the user experience. By using this site, you consent to the placement of these cookies. Click Accept to consent and dismiss this message or Deny to leave this website. Read our Privacy Statement for more.
Join Mailing List   |   Jobs   |   Print Page   |   Contact Us   |   Sign In   |   Join
News & Press: Opportunities for Participation

New ISTH REDCap Registry Seeks Data on Cancer Patients on Concurrent Cancer Therapies and DOACs

Thursday, April 25, 2019  
Share |

Participate in this new ISTH REDCap registry: An International Registry of the Safety and Efficacy in Cancer Patients With Concurrent Use of Direct Oral Anticoagulants and Targeted Cancer Therapies. See the description below:

We are collecting data from ISTH members who take care of cancer patients who are on concurrent targeted cancer therapy and direct oral anticoagulants (DOACs), as both are increasingly used in the cancer population and the safety of combined use is unclear. An ISTH international registry has been designed to investigate this issue. This is an observational registry, for patients between age 18-89 who has active malignancy taking one of the selected oral targeted cancer therapies and concurrent DOACs. Patient data will be entered into an on-line redcap database at two time points, at the time of start of concurrent use and outcomes after 6 months. We aim for a sample size of 100 for patients on DOAC for VTE and 100 with atrial fibrillation.

Centers will be compensated for $100 USD per patient after data are entered for both time points, as an appreciation for your time and work.

Please contact Tzu-Fei Wang, M.D. at for more information if interested or more questions. We appreciate your contribution.

Click here to begin the survey.


Membership Management Software Powered by YourMembership  ::  Legal